Alnylam Pharmaceuticals, Inc. (ALNY) is around the top of the Biotechnology industry according to InvestorsObserver. ALNY received an overall rating of 42, which means that it scores higher than 42 percent of all stocks. Alnylam Pharmaceuticals, Inc. also achieved a score of 67 in the Biotechnology industry, putting it above 67 percent of Biotechnology stocks. Biotechnology is ranked 111 out of the 148 industries.
Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 42 would rank higher than 42 percent of all stocks.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.
Alnylam Pharmaceuticals, Inc. (ALNY) stock has risen 0.71% while the S&P 500 has fallen -0.92% as of 11:42 AM on Friday, Jun 18. ALNY is up $1.23 from the previous closing price of $172.25 on volume of 308,707 shares. Over the past year the S&P 500 has gained 34.27% while ALNY is up 22.18%. ALNY lost -$7.55 per share the over the last 12 months.
Click Here to get the full Stock Score Report on Alnylam Pharmaceuticals, Inc. (ALNY) Stock.
Visit link:
Is Alnylam Pharmaceuticals, Inc. (ALNY) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Recommendation and review posted by G. Smith
